In addition, the experiments with lymphoma-prone transgenic mouse models showed that malignant B cells with a c-MYC activation are highly sensitive to loss to DDX3, suggesting a synthetic lethality between gain of MYC and loss of DDX3 function that could be exploited by small molecule inhibitors. The gene discussed is MYC; the disease is lymphoma.